Indinavir-Associated Toxicity Mimicking Urinary Tuberculosis in a Patient with AIDS

Vinicius Daher Alvares Delfino¹, Natally Marques Santiago¹, Altair Jacob Mocelin¹, Luiz Fernando Kunii¹ and André Luiz Bortoliero²
¹Nephrology Department; ²Infectious Disease Department, State University of Londrina; Londrina, PR, Brazil

This case reported to a patient with AIDS who presented persistent sterile leukocyturia and hematuria, lower back pain, bladder suffering symptoms, and renal papillary necrosis which were thought to be secondary to urinary tuberculosis but were demonstrated to be indinavir-associated side effects. The intention of this report is to remind medical professionals involved in the care of HIV+ patients of this possible association in order to avoid unnecessary investigation and to stress the need of careful periodical assessment of renal function and urinalysis in patients treated with indinavir.

Key-Words: Hematuria, indinavir, kidney papillary necrosis, tuberculosis.

As nowadays sustained viral suppression can be obtained through chronic highly active antiretroviral treatment to patients with HIV infection, long-term drug side effects should be feared. Indinavir (IDV) is one of the most widely used protease inhibitor. Reported side effects include lipodystrophy, hyperbilirubinemia, gastrointestinal malaise, diarrhea and headache. Nephrolithiasis is the most common renal side effect, being reported in 4-9% of individuals [1], but the spectrum of renal and urinary adverse effects of IDV is much larger, as it can be appreciated in the case here presented.

Case Report

A 47 year-old asian-descendant man was diagnosed as having AIDS in October 1996 and started on a fixed combination of zidovudine 300 mg and lamivudine 150 mg, twice daily, plus indinavir (IDV), 800 mg thrice daily. This therapeutic regimen led to gradual normalization of CD4+ cells and, from September 1998 onwards, to undetectable RNA virus levels on the blood. The patient’s clinical course went uneventful until May 2001 when sterile leukocyturia and hematuria were found on routine urinalysis. The sterile leukocyturia and hematuria were persistent and raised the suspicious of urinary tuberculosis. The urinary tract was shown to have normal ultrasonographic appearance and a cystoscopy was performed but was unrevealing; multiple urinary cultures for Mycobacterium were ordered but were negative. From August 2002 on he started presenting repeated episodes of bilateral lower back pain. An intravenous pyelography was ordered but did not reveal stones or any other abnormality. On February 2003 his serum creatinine increased from 1.16 mg/dL (June 1997; estimated glomerular filtration rate, MDRD simplified formula, eGFR, 72 mL/min/1.73 m²) to 1.57 mg/dL (eGFR, 44 mL/min/1.73 m²). It was suspected that the renal and urologic patient’s abnormalities might be due to indinavir-associated toxicity. After discussion of the case with the infectologist in charge for the case it was agreed to change from indinavir to atazanavir (400 mg/day). With the change, he had progressive normalization of his urinary sediment and disappearance of urinary symptoms, while keeping undetectable serum HIV-RNA blood levels. The course of leukocyturia and eGFR after medication change are depicted on Figure 1. It should be said, however, that even after more then 20 months of indinavir withdrawal his serum creatinine persisted elevated (1.5 mg/dL; eGFR 51 mL/min/1.73 m²) and there was abnormal renal corticomedullar differentiation at the ultrasound.

Discussion

In this AIDS patient, the sterile leukocyturia/hematuria accompanied by bladder suffering symptoms, and recurrent lower back pain were suggestive for urinary tuberculosis, which may also cause renal papillary necrosis. However, the complete disappearance of the urinary symptoms and the normalization of the patient’s urinalysis (which were long time persistent) with the stop of IDV strongly point out for a causal relationship between IDV use and patient’s renal/urologic nephrotoxicity. Indeed, all patient’s findings, including renal papillary necrosis, have been reported as associated with indinavir use [2,3]. The fact that there was only a slight improvement in patient’s renal function even many months after the discontinuation of IDV, in conjunction with ultrasound findings of abnormal renal corticomedullar differentiation may suggest that chronic renal parenchymal damage related to the drug use may have occurred [4]. Indinavir is metabolized primarily in the liver, but renal excretion of parent drug accounts for approximately 10% of a dose. In order to avoid renal and urological side-effects of the drug, it is...
recommended for patients who start on indinavir a periodically monitoring during the first six months of therapy, then biannually thereafter for changes in renal function and pyuria. Prevention of indinavir crystalluria and nephrolithiasis depends on maintenance of a daily fluid intake of at least 1.5 to 2 L [3].

References